{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:22:22Z","timestamp":1790799742480,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.diagmicrobio.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T03:18:09Z","timestamp":1542856689000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies"],"prefix":"10.1016","volume":"94","author":[{"given":"Ana F.","family":"Oliota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suelem T.","family":"Penteado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia C.","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0005","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/cid\/cit453","article-title":"Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin b in critically ill patients at a tertiary care medical center","volume":"57","author":"Akajagbor","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1055\/s-0034-1371361","article-title":"Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii","volume":"31","author":"Alan","year":"2014","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00238-013-0827-2","article-title":"Colistin effectiveness and nephrotoxicity: experience from a tertiary care burns unit in Oman","volume":"36","author":"Al-Busaidi","year":"2013","journal-title":"Eur J Plast Surg"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0020","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s15010-013-0471-6","article-title":"Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients","volume":"41","author":"Averbuch","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MCC.0000000000000453","article-title":"Drug-induced kidney disease in the ICU: mechanisms, susceptibility, diagnosis and management strategies","volume":"23","author":"Awdishu","year":"2017","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0030","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3109\/00365548.2014.926021","article-title":"Colistin nephrotoxicity increases with age","volume":"46","author":"Balkan","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0035","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10096-014-2070-6","article-title":"Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections","volume":"33","author":"Batirel","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0040","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure \u2014 definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ajhp\/62.1.39","article-title":"Use of colistin in the treatment of multiple-drug-resistant gram-negative infections","volume":"62","author":"Berlana","year":"2005","journal-title":"Am J Heal Pharm"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0050","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2015.03.020","article-title":"The efficacy and nephrotoxicity associated with colistin use in an intensive care unit in Vietnam: use of colistin in a population of lower body weight","volume":"35","author":"Binh","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0060","first-page":"1168","article-title":"Toxicity of colistin in cystic fibrosis patients","volume":"25","author":"Bosso","year":"1991","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5152\/ced.2014.1821","article-title":"Intravenous colistin use in children: single-center experience","volume":"8","author":"Cagan","year":"2014","journal-title":"\u00c7ocuk Enfeksiyon Dergisi\/Journal Pediatr Infect"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0070","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00508-015-0773-z","article-title":"Variables determining the development of colistin-associated renal impairment","volume":"128","author":"Ceylan","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2009.11.016","article-title":"Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections","volume":"35","author":"Cheng","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2334-14-102","article-title":"Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumanniiin a critical setting: a matched cohort analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0085","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/phar.1271","article-title":"Emergent renal dysfunction with colistin pharmacotherapy","volume":"33","author":"Collins","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365548.2013.844350","article-title":"Epidemiology and outcome of infections with carbapenem-resistant gram-negative bacteria treated with polymyxin B\u2013based combination therapy","volume":"46","author":"Crusio","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0095","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/cis286","article-title":"High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study","volume":"54","author":"Dalfino","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0100","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/cid\/civ717","article-title":"Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study","volume":"61","author":"Dalfino","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0105","doi-asserted-by":"crossref","first-page":"179.e1","DOI":"10.1016\/j.cmi.2014.07.010","article-title":"Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins","volume":"21","author":"de Oliveira","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0110","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1128\/AAC.01707-09","article-title":"Colistin dosing and nephrotoxicity in a large community teaching hospital","volume":"54","author":"DeRyke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0115","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4103\/0972-5229.136070","article-title":"Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration","volume":"18","author":"Dewan","year":"2014","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0120","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1592\/phco.30.10.973","article-title":"Methods in epidemiology: observational study designs","volume":"30","author":"DiPietro","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0125","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1592\/phco.31.12.1257","article-title":"Nephrotoxicity associated with intravenous colistin in critically ill patients","volume":"31","author":"Doshi","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0130","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1128\/AAC.00510-13","article-title":"Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections","volume":"57","author":"Dubrovskaya","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0135","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/jac\/dkv014","article-title":"Risk factors for nephrotoxicity onset associated with polymyxin B therapy","volume":"70","author":"Dubrovskaya","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0140","first-page":"1","article-title":"Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically ill patients with multidrug-resistant gram-negative pneumonia","author":"Elefritz","year":"2016","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0145","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/jac\/dkq285","article-title":"The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic","volume":"65","author":"Elias","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0150","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0160","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijantimicag.2005.09.004","article-title":"Nephrotoxicity of intravenous colistin: a prospective evaluation","volume":"26","author":"Falagas","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0165","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1469-0691.2006.01559.x","article-title":"Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant gram-negative bacterial infections","volume":"12","author":"Falagas","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0170","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2009.10.005","article-title":"Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10096-014-2233-5","article-title":"Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients","volume":"34","author":"Freire","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0180","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.burns.2009.07.010","article-title":"Use of colistin in treating multi-resistant gram-negative organisms in a specialised burns unit","volume":"36","author":"Ganapathy","year":"2010","journal-title":"Burns"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000356004","article-title":"Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"59","author":"Garnacho-Montero","year":"2013","journal-title":"Chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0190","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/AAC.01414-15","article-title":"Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant gram-negative bacilli","volume":"60","author":"Gibson","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0195","author":"Greenwood Village"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7883\/yoken.JJID.2014.501","article-title":"Risk factors for colistin-associated acute kidney injury: a multicenter study from Turkey","volume":"69","author":"Gul","year":"2016","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0205","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/599225","article-title":"Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center","volume":"48","author":"Hartzell","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0210","series-title":"The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0215","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0220","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1345\/aph.1H353","article-title":"Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit","volume":"40","author":"Holloway","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0225","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5262\/tndt.2014.1003.04","article-title":"Colistin and acute renal failure: a centre's experience","volume":"23","author":"H\u00fcr","year":"2014","journal-title":"Turk Nephrol Dial Transplant J"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0230","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s15010-013-0522-z","article-title":"Colistin therapy for multidrug-resistant gram-negative infection: clinical outcome and risk factors","volume":"41","author":"Jun","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0235","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.2174\/09298673113209990185","article-title":"The renaissance of polymyxins","volume":"20","author":"Kadar","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0240","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10156-012-0430-7","article-title":"Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?","volume":"18","author":"Kalin","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s15010-013-0495-y","article-title":"Comparison of colistin and colistin\/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"42","author":"Kalin","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0250","first-page":"1137","article-title":"Efficacy of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia\/sepsis","volume":"30","author":"Karabay","year":"2014","journal-title":"Acta Med Mediterr"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0255","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/INF.0000000000000117","article-title":"The use of Colistin in critically ill children in a pediatric intensive care unit","volume":"33","author":"Karbuz","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0260","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.49.8.3136-3146.2005","article-title":"Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis","volume":"49","author":"Kasiakou","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/phar.1510","article-title":"To B or not to B, that is the question: is it time to replace colistin with polymyxin B?","volume":"35","author":"Kassamali","year":"2015","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0270","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0275","first-page":"1","article-title":"Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0280","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1159\/000320746","article-title":"Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin","volume":"117","author":"Ko","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0285","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-72-6-857","article-title":"Adverse effects of sodium colistimethate \u2014 manifestations and specific reaction rates during 317 courses of therapy","volume":"72","author":"Koch-Weser","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0290","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5001\/omj.2016.62","article-title":"Evaluation of risk factors for intravenous colistin use-related nephrotoxicity","volume":"31","author":"Koksal","year":"2016","journal-title":"Oman Med J"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jinf.2012.01.015","article-title":"Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy","volume":"65","author":"Kubin","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0300","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13312-015-0586-1","article-title":"Safety and efficacy of intravenous colistin in children","volume":"52","author":"Kumar","year":"2015","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0305","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/dkq390","article-title":"Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia","volume":"66","author":"Kvitko","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0310","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijantimicag.2009.12.002","article-title":"Predictors of acute kidney injury associated with intravenous colistin treatment","volume":"35","author":"Kwon","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0315","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1248\/bpb.b13-00109","article-title":"Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii","volume":"37","author":"Kwon","year":"2014","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0320","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijantimicag.2015.01.011","article-title":"Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: incidence of nephrotoxicity and outcomes","volume":"45","author":"Kwon","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0325","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/CCM.0000000000000931","article-title":"Association between colistin dose and development of nephrotoxicity","volume":"43","author":"Lee","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0330","first-page":"109","article-title":"Incidencia de nefrotoxicidad en pacientes infectados, tratados con colistimetato","volume":"33","author":"Leonor","year":"2013","journal-title":"Enfermedades Infecc y Microbiol"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3346\/jkms.2011.26.3.325","article-title":"The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections","volume":"26","author":"Lim","year":"2011","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0340","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijantimicag.2015.09.011","article-title":"Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis","volume":"46","author":"Liu","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0345","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.21037\/atm.2017.03.75","article-title":"Poor outcome reporting in medical research; building practice on spoilt grounds","volume":"5","author":"Mantziari","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0350","first-page":"108","article-title":"Insuficiencia renal aguda asociada al tratamiento con colist\u00edn en unidad de cuidados intensivos","volume":"34","author":"Mart\u00ednez","year":"2014","journal-title":"Nefrol Di\u00e1lisis y Transpl"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0355","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/SLA.0000000000001573","article-title":"Underreporting of secondary endpoints in randomized trials","volume":"264","author":"Matthews","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0360","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0365","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1345\/aph.1M277","article-title":"Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use","volume":"43","author":"Mendes","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0370","first-page":"241","article-title":"Correlaci\u00f3n entre dosis acumulada de colistimetato intravenoso y nefrotoxicidad en pacientes hospitalizados","volume":"31","author":"Meza-Oviedo","year":"2015","journal-title":"Med Interna Mex"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0375","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (reprinted from annals of internal medicine)","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0380","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-009-8342-x","article-title":"Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections","volume":"37","author":"Montero","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0385","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1128\/AAC.01329-12","article-title":"Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients","volume":"57","author":"Mostardeiro","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0390","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/0972-5229.120319","article-title":"To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B","volume":"17","author":"Nandha","year":"2013","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0395","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0400","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3109\/23744235.2015.1055586","article-title":"High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant Acinetobacter baummannii in critically ill cancer patients: a retrospective cohort study","volume":"47","author":"Nazer","year":"2015","journal-title":"Infect Dis (Auckl)"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0405","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1128\/AAC.00844-15","article-title":"Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant gram-negative rods","volume":"59","author":"Nelson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0410","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/jac\/dkn128","article-title":"Ampicillin\/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp","volume":"61","author":"Oliveira","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0415","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.diagmicrobio.2009.07.018","article-title":"Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity","volume":"65","author":"Oliveira","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0420","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12941-015-0062-8","article-title":"High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia","volume":"14","author":"Omrani","year":"2015","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0425","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/AAC.47.8.2659-2662.2003","article-title":"Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria","volume":"47","author":"Ouderkirk","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0430","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/jac\/dkq069","article-title":"Effectiveness and safety of colistin: prospective comparative cohort study","volume":"65","author":"Paul","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0435","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.00871-13","article-title":"Clinical experience of colistin-glycopeptide combination in critically ill patients infected with gram-negative bacteria","volume":"58","author":"Petrosillo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0440","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/AAC.02476-13","article-title":"In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin b therapy","volume":"58","author":"Phe","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0445","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jinf.2008.01.003","article-title":"Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria","volume":"56","author":"Pintado","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0450","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/cir611","article-title":"Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system","volume":"53","author":"Pogue","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0455","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijantimicag.2016.11.001","article-title":"Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?","volume":"48","author":"Pogue","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0460","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cmi.2017.02.023","article-title":"Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing","volume":"23","author":"Pogue","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0465","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40272-015-0133-5","article-title":"Treatment of ventilator-associated pneumonia using intravenous colistin alone or in combination with inhaled colistin in critically ill children","volume":"17","author":"Polat","year":"2015","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0470","first-page":"820","article-title":"Carbapenem resistant gram-negative bacteremia in an Indian intensive care unit: a review of the clinical profile and treatment outcome of 50 patients","volume":"18","author":"Porwal","year":"2014","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0475","first-page":"59","article-title":"Recent advances and perspectives in the design and development of polymyxins","volume":"13","author":"Rabanal","year":"2017","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0480","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.02634-15","article-title":"Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B","volume":"60","author":"Rigatto","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0485","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1183\/09031936.00156906","article-title":"Ventilator-associated pneumonia due to colistin susceptible-only microorganisms","volume":"30","author":"Rios","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0490","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/cc12853","article-title":"Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and\/or other nephrotoxic antibiotics: a retrospective cohort study","volume":"17","author":"Rocco","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0495","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cpt1970111106","article-title":"Serum electrolyte abnormalities associated with the administration of polymyxin B in febrile leukemic patients","volume":"11","author":"Rodriguez","year":"1970","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0500","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/00365540903147001","article-title":"Nephrotoxicity associated with the use of intravenous colistin","volume":"41","author":"Santamar\u00eda","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0505","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4103\/0253-7613.121373","article-title":"Parenteral polymyxins: assessing efficacy and safety in critically ill patients with renal dysfunction","volume":"45","author":"Sekhri","year":"2013","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0510","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1186\/s12879-014-0626-9","article-title":"Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study","volume":"14","author":"Siddiqui","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0515","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/jac\/dkh369","article-title":"Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections","volume":"54","author":"Sobieszczyk","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0520","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorl\u00ed","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0525","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1146\/annurev.bi.46.070177.003451","article-title":"Polymyxin and related peptide antibiotics","volume":"46","author":"Storm","year":"1977","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0530","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5935\/0103-507X.20130051","article-title":"Parenteral colistin for the treatment of severe infections: a single center experience","volume":"25","author":"Tanita","year":"2013","journal-title":"Rev Bras Ter Intensiva"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0535","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7883\/yoken.JJID.2014.223","article-title":"Incidence and risk factors for colistin-associated nephrotoxicity","volume":"68","author":"Temocin","year":"2015","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0540","first-page":"301","article-title":"Monitoring of effectiveness and safety of colistin for therapy in resistant gram-negative bacterial infections in hospitalized patients at Siriraj hospital","volume":"99","author":"Thamlikitkul","year":"2016","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0545","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10156-013-0549-1","article-title":"Impact of the initiation time of colistin treatment for Acinetobacter infections","volume":"19","author":"Tigen","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0550","first-page":"353","article-title":"The risk factors of colistin methanesulfonate associated nephrotoxicity Indian","volume":"20","author":"Tigen","year":"2016","journal-title":"J Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0555","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","article-title":"Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet?","volume":"48","author":"Tran","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0560","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000442786","article-title":"Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series","volume":"61","author":"Trifi","year":"2015","journal-title":"Chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0565","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijantimicag.2013.12.002","article-title":"Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium","volume":"43","author":"Tuon","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0570","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijantimicag.2016.07.023","article-title":"Colistin versus polymyxin B for the treatment of patients with multidrug-resistant gram-negative infections: a systematic review and meta-analysis","volume":"49","author":"Vardakas","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0575","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jrsm.1122","article-title":"Combining randomized and non-randomized evidence in clinical research: a review of methods and applications","volume":"6","author":"Verde","year":"2015","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0580","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/cis909","article-title":"Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia","volume":"56","author":"Vicari","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0590","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0595","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10156-012-0451-2","article-title":"Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens","volume":"19","author":"Yilmaz","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0600","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3855\/jidc.6195","article-title":"Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia","volume":"9","author":"Yilmaz","year":"2015","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0605","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/MJT.0b013e3182a32df3","article-title":"Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous Colistin and intravenous ampicillin-sulbactam","volume":"23","author":"Zalts","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.diagmicrobio.2018.11.008_bb0610","doi-asserted-by":"crossref","first-page":"e02319-16","DOI":"10.1128\/AAC.02319-16","article-title":"Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?","volume":"61","author":"Zavascki","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318306382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318306382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:58:52Z","timestamp":1775278732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318306382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0732889318306382"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.11.008","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}